Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin
about
Imatinib in chronic myeloid leukemia: an overviewTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Selecting the best frontline treatment in chronic myeloid leukemiaTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaGranulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.The choice of first-line chronic myelogenous leukemia treatment.Re-emergence of interferon-α in the treatment of chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.How I treat newly diagnosed chronic phase CMLTargeting survival pathways in chronic myeloid leukaemia stem cellsFront-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.Chronic myeloid leukemia: overview of new agents and comparative analysis.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.Tyrosine kinase inhibitors and interferon.The interferon-alpha revival in CML.Update on emerging treatments for chronic myeloid leukemia.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.Chronic myeloid leukemia: First-line drug of choice.Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations.Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era
P2860
Q26865086-1B9B6627-9EA9-4987-868D-9B9A2EE32030Q30242015-390EE63F-4D38-4B63-BF4F-AD59D3E6FC2FQ33764253-BE32AD5C-FD32-413F-A4E0-393F01C34185Q33806617-47DE21F4-077A-437B-8A46-C13A55BD8AF3Q34055591-19C1E17C-D8E7-473B-8B33-8CD6C68F31B7Q34272962-D6CE086A-DB35-4446-B05E-D172586F7C8CQ35221071-6EF82F1E-E68A-486C-A898-08ABDA25A688Q36989407-4F2BD3DF-2B96-40F7-9404-B7A1D0C1F056Q37026032-FB2001FB-63DF-4279-9A69-E029F41D401BQ37027767-E5EAAA2E-D76B-4592-8A94-CBDB1DD9058DQ37122686-F266A30C-1D47-4276-80A0-A4EAA3A901ABQ37827278-177C08C1-9D5B-446E-A19E-B66D3E783D45Q37896015-05EF4C43-007A-4F90-92F2-66E244B01097Q38097728-C869A851-0330-4304-B846-0A9516ED9290Q38148233-5210A4BE-CD08-44D1-BB86-54A1E073A42EQ38181113-9B45DA54-3C69-4E98-B9C3-6F0942C95635Q38392694-25F01EF8-B394-49FA-A515-0D02A297BD8BQ38397515-06B5621D-5150-4A7E-A430-D3B87B61F106Q38598820-93ABB792-A7C6-46F0-B90D-77A91E70AB28Q38697314-4A26773A-F32A-4606-89DA-362AAE145CC9Q41832483-3723ADCF-B415-46E1-9525-1B054C9B5586Q42391592-B4AF8F74-3E4E-4EB7-ABC2-44A6DF3D32C3Q47136084-33908423-06DC-492B-9FEB-68E3B12FBA23Q58449026-68C76E78-BF06-4C7D-A34E-C3FC7DF0F6FF
P2860
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@ast
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@en
type
label
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@ast
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@en
prefLabel
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@ast
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@en
P2093
P2860
P50
P356
P1433
P1476
Immune modulation of minimal r ...... e-macrophage colony-stimulatin
@en
P2093
Alfonso Quintás-Cardama
Charles Koller
Jenny Shan
Jody Hiteshew
P2860
P304
P356
10.1002/CNCR.25438
P407
P50
P577
2010-09-30T00:00:00Z